Marjolein Pompen

Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands

H.G.M. van Haalen, Marjolein Pompen, Klas Bergenheim et al. · Clinical Drug Investigation · 2013 · 44 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +14

Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and Germany

Bernhard Saller, Anders Mattsson, Peter Herbert Kann et al. · European Journal of Endocrinology · 2006 · 44 citations

Pharmacy, Endocrinology, Health Assessment +8

Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands

Marjolein Pompen, Murat Gök, Annoesjka Novák et al. · Lung Cancer · 2008 · 42 citations

Medicine, Oncology, Pharmacoeconomics +14

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

Brigitte A.B. Essers, Shanley C. Seferina, Vivianne C. G. Tjan‐Heijnen et al. · Value in Health · 2010 · 38 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +16

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands

Jelena Stevanović, Marjolein Pompen, Hoa H. Le et al. · PLoS ONE · 2014 · 36 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17